Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 4 1

Status

Completed 5

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Gynecologic 2

Conditions

Uterine Cervical Neoplasms 8Condylomata Acuminata 7Papillomavirus Infections 5Vulvar Neoplasms 2Vaginal Neoplasms 2Uterine Cervical Dysplasia 1Neoplasms 1Cancer Survivor 1

Interventions

human papillomavirus vaccine, L1 type 16, 18 35Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 23Papillomavirus Vaccines 14Data Collection 7Blood Specimen Collection 7Vaccines 6Vaccines, Synthetic 5Educational Status 5Radiotherapy, Intensity-Modulated 4Human Papillomavirus Recombinant Vaccine nonavalent 4Early Intervention, Educational 4Vaginal Smears 3Surveys and Questionnaires 3Polymerase Chain Reaction 3Paclitaxel 3Methods 3Engerix-B 3Colposcopy 3Cisplatin 3halofantrine 2fludarabine phosphate 2fludarabine 2aldesleukin 2Watchful Waiting 2Taxes 2Patient Navigation 2Papanicolaou Test 2Observation 2Light Coagulation 2Imiquimod 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Completed × Papillomavirus Infections × Vaccines, Synthetic × Clear all
NCT05435209 2023-11-29

Effectiveness of the Q-HPV Vaccine 9-years Post Vaccination Among HIV Positive Adolescents

University of Washington

Phase 4 Completed
158 enrolled

Papillomavirus Infections

NCT01245764 2018-11-14

GARDASILâ„¢ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046)

Merck Sharp & Dohme LLC

Phase 3 Completed
250 enrolled 20 charts
Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections

NCT00411749 2017-04-21

V501 Immunogenicity Study in Females Age 9 to 17 Years (V501-028)

Merck Sharp & Dohme LLC

Phase 2 Completed
107 enrolled 12 charts

Papillomavirus Infections

NCT00496626 2017-04-17

An Immunogenicity and Safety Study of Gardasil® in Chinese Subjects (V501-030)(COMPLETED)

Merck Sharp & Dohme LLC

Phase 3 Completed
600 enrolled 12 charts

Papillomavirus Infections

NCT00551187 2015-06-08

A Study to Evaluate Tolerability and Immunogenicity of V504 Administered Concomitantly With GARDASIL (V504-001)(COMPLETED)

Merck Sharp & Dohme LLC

Phase 2 Completed
620 enrolled
Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡